Aptamers can be developed
for biosensors, diagnostic tools, and
therapeutic reagents. These applications usually require a fusion
of aptamers and expression platforms. However, the fusion process
is usually time-consuming and laborious. In this study, we integrated
the deoxyribozyme (I-R3) as an expression platform in the SELEX cycle
(called Expression-SELEX) to select aptazymes that can sense diverse
molecules. We used the Maple syrup urine disease (MSUD) biomarker
L-allo-isoleucine to test the selection model. After five rounds of
screening, the cleavage products were sufficiently enriched to be
visualized on polyacrylamide gel electrophoresis (PAGE) gel. Through
high-throughput sequencing analysis, several candidates were identified.
One such candidate, IR3-I-DNA, binds L-allo-isoleucine with a dissociation
constant (
K
D
) of 0.57 mM. When the ligand
was present, the cleavage fraction of IR3-I-DNA increased from 0.3
to 0.5, and its
K
obs
value improved from
1.38 min
–1
to 1.97 min
–1
. Our
selection approach can also be applied to produce aptazymes that can
bind to variable ligands and be used more directly as biosensors.